Phase IV Study of Chronic Infusional Epoprostenol for Severe Primary Pulmonary Hypertension

Summary

OBJECTIVES: I. Provide epoprostenol (Flolan, prostaglandin I2) by chronic infusion to patients with severe primary pulmonary hypertension for whom no alternative therapy is available. II. Obtain additional safety information on continuous infusion epoprostenol. III. Obtain additional information on economic resource health consumption.

Timeline

Start

1993-08

Primary completion

—

Completion

—

Drugs

Indications